The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer

Long Wang,1,* Tiantian Shi,1,* Li Feng,1 Zhisong Fan,1 Xiaoli Xu,2 Xinliang Zhou,1 Xue Zhang,1 Jing Han,1 Li Jing,1 Jiayin Liu,1 Yujie Shan,1 Fengling Liu,1 Jing Zuo,1 Yudong Wang1 1Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People&rsqu...

Full description

Bibliographic Details
Main Authors:	Wang L, Shi T, Feng L, Fan Z, Xu X, Zhou X, Zhang X, Han J, Jing L, Liu J, Shan Y, Liu F, Zuo J, Wang Y
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-03-01
Series:	Cancer Management and Research
Subjects:	metastasis non-small cell lung cancer egfr mutations icotinib prognostic value
Online Access:	https://www.dovepress.com/the-prognostic-value-of-baseline-distant-metastasis-in-icotinib-treate-peer-reviewed-article-CMAR

Similar Items

Clinical Analysis of Icotinib on Beneficiary of  Advanced Non-small Cell Lung Cancer with EGFR Common Mutation
by: Xiaowen JIANG, et al.
Published: (2016-04-01)

Prognostic Factors in Patients with Advanced Lung Adenocarcinoma Treated with Icotinib
by: ZHANG Hongbin, et al.
Published: (2022-11-01)

The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells
by: Zhu L, et al.
Published: (2020-11-01)

Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo
by: Tianze Liu, et al.
Published: (2019-04-01)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
by: Junhui Wang, et al.
Published: (2019-02-01)

Real-world Study of Icotinib in EGFR Mutant Non-small Cell Lung Cancer  Based on the Therapeutic Drug Monitoring
by: Sen HAN, et al.
Published: (2025-01-01)

Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
by: Xiaojie Chen, et al.
Published: (2022-11-01)

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion
by: Lanzi Ou, et al.
Published: (2022-07-01)

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial
by: Liu YT, et al.
Published: (2020-06-01)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
by: Kejun Liu, et al.
Published: (2020-01-01)

Clinical Effects for Patients with Recurrent Advanced Non-small Cell Lung Cancer Treated with Icotinib Hydrochloride
by: Jingying NONG, et al.
Published: (2013-05-01)

Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR
by: Faisal A. Almalki, et al.
Published: (2021-10-01)

Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation
by: Jianxin Chen, et al.
Published: (2022-07-01)

Comparison of the Efficacy and Safety of Icotinib with Standard Second-line  Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer
by: Shuyang YAO, et al.
Published: (2015-06-01)

Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trialResearch in context
by: Wei Ou, et al.
Published: (2023-03-01)

Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations: A retrospective study
by: Zhansheng Jiang, et al.
Published: (2021-09-01)

The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism
by: Qi Zhou, et al.
Published: (2023-12-01)

Effects of Docetaxel Combined with Icotinib on Serum Tumor Markers and Quality of Life of Patients with Advanced Non-Small Cell Lung Cancer
by: Huawei LIN, et al.
Published: (2020-10-01)

Clinical Observation of Icotinib Hydrochloride in First-line Therapy  for Pulmonary Adenocarcinoma
by: Xinjie YANG, et al.
Published: (2013-07-01)

Essential role for STAT3/FOXM1/ATG7 signaling-dependent autophagy in resistance to Icotinib
by: Xin Lyu, et al.
Published: (2022-06-01)

Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique
by: Yangchun Gu, et al.
Published: (2021-12-01)

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
by: Long-fei Mao, et al.
Published: (2020-09-01)

A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion
by: Xiaohong Xie, et al.
Published: (2020-06-01)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
by: Soei Gen, et al.
Published: (2022-06-01)

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study
by: Linlin Zhang, et al.
Published: (2023-08-01)

Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1
by: Xuewei Cheng, et al.
Published: (2017-11-01)

Inhibition of miR-22 enhanced the efficacy of icotinib plus pemetrexed in a rat model of non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2020-03-01)

Brain metastasis in non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations: a report of seven cases and literature review
by: Puchun Er, et al.
Published: (2017-08-01)

Icotinib inhibits proliferation and epithelial-mesenchymal transition of non-small cell lung cancer A549 cells
by: Guohai Wang, et al.
Published: (2019-08-01)

Association between EGFR, ALK and KRAS Gene Status and Synchronous Distant  Organ Metastasis in Non-small Cell Lung Cancer
by: Ge GAO, et al.
Published: (2018-07-01)

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report
by: Eric Dansin, et al.
Published: (2015-03-01)

LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung adenocarcinoma
by: Jie Wu, et al.
Published: (2021-01-01)

Rapid vision improvement by using icotinib in a patient with bilateral choroidal metastases symmetrically from lung cancer
by: Chaoran Li, et al.
Published: (2023-07-01)

The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports
by: Yamin Meng, et al.
Published: (2023-09-01)

Analysis of Clinicopathological Feature and Prognosis for  Leptomeningeal Metastasis in Non-small Cell Lung Cancer
by: Min ZHU, et al.
Published: (2016-08-01)

Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma
by: Zheng H, et al.
Published: (2019-07-01)

Acute generalized exanthematous pustulosis induced by icotinib: a case report and literature review
by: Wei Yang, et al.
Published: (2024-08-01)

EGFR‐mutated stage IV non‐small cell lung cancer: What is the role of radiotherapy combined with TKI?
by: Bailong Liu, et al.
Published: (2021-09-01)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
by: Gao X, et al.
Published: (2019-11-01)

Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review
by: Carmine Valenza, et al.
Published: (2021-08-01)